ArticleJournal of advanced research2025
Nanoparticle-mediated celastrol ER targeting delivery amplify immunogenic cell death in melanoma.
Article in Journal of advanced research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Tripterine Liposome Exerts Antitumor and Immunomodulatory Effects in Pancreatic Ductal Adenocarcinoma.MedComm · 2026Article
- Nanomaterial-driven spatiotemporal autophagy modulation: The dual-edged sword in precision cancer therapy.Acta pharmaceutica Sinica. B · 2026Review
- Augmented therapeutic efficacy of Erianin through pH-responsive charge-reversal liposome integrated synergistic PTT and PDT in breast cancer.Journal of pharmaceutical analysis · 2026Article
- Endoplasmic Reticulum-Targeting NIR Cyanine ER800 Nanoparticles Promote Pyroptosis in Triple-Negative Breast Cancer.ACS applied materials & interfaces · 2026Article
- The Antitumor Potential of Celastrol: Research Progress on Antitumor Mechanisms and Strategies for Toxicity Reduction with Efficacy Enhancement.Biomolecules · 2026Review
- Construction of Transcutaneous Immuno-oncology Vaccine Patches Based on Total RNA from Immunogenic Cell Death-Induced Tumor Cells: Characterization, Immunological Activity, and Safety Evaluation.Applied biochemistry and biotechnology · 2026Article
- Osteoarthritis: molecular pathogenesis and potential therapeutic options.Signal transduction and targeted therapy · 2026Review
- Spatiotemporally Controlled Tumor Photodynamic/Immunotherapy Therapy Based on Upconversion Hybrid Nanosystem.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Therapeutic targeting of cell death-immune crosstalk in cancer to rewire the tumor immune microenvironment.Molecular cancer · 2025Review
- A Comprehensive Review of Smart Thermosensitive Nanocarriers for Precision Cancer Therapy.International journal of molecular sciences · 2025Review
- Injectable celastrol-loading emulsion hydrogel for immunotherapy of low-immunogenic cancer.Journal of nanobiotechnology · 2025Article
- Carrier-Free Nanomedicine Based on Celastrol and Methotrexate for Synergistic Treatment of Breast Cancer via Folate Targeting.International journal of nanomedicine · 2025Article
- Recent Trends in anti-tumor mechanisms and molecular targets of celastrol.International journal of biological sciences · 2024Review
- Lactoferrin docking NIR-II cyanine dye as a potentiated phototheranostic for synchronous multimodal bioimaging and tumor photo-immunotherapy.Theranostics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChemoimmunotherapy, which benefits from the combination of chemotherapy and immunotherapy, has emerged as a promising strategy in cancer treatment. However, effectively inducing a robust immune response remains challenging due to the limited responsiveness across patients. Endoplasmic reticulum (ER) stress is essential for activating intracellular signaling pathways associated with immunogenic cell death (ICD), targeting drugs to ER might enhance ER stress and improve ICD-related immunotherapy.
objectivesTo improve the immune response of Chemoimmunotherapy.
methodsER targeting nanoparticles TSE-CEL/NP were constructed to enhance immunogenic cancer cell death. Flow cytometry, confocal microscope, TEM and immunofluorescence were used to evaluate the ER targeting effect and immunogenic tumor cell death in vitro on B16F10 tumor cells. Unilateral and bilateral tumor models were constructed to investigate the efficacy of anti-tumor and immunotherapy in vivo. Lung metastasis B16F10 melanoma tumor-bearing mice were used to assess the anti-metastasis efficacy.
resultsTSE-CEL/NP could specially accumulate in ER, thereby induce ER stress. High ER stress trigger the exposure of CRT, the extracellular release of HMGB1 and ATP. These danger signals subsequently promote the recruitment and maturation of dendritic cells (DCs), which in turn increase the proliferation of cytotoxic T lymphocytes (CD8
conclusionOur findings demonstrated that celastrol ER targeting delivery could amplify immunogenic cell death in melanoma, which provide experimental basis for melanoma immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.